(Q37009125)

17 August 2017

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer (English)

1 reference

17 August 2017

1 reference

1 reference

Rachel M Layman

1

1 reference

17 August 2017

Amy S Ruppert

2

1 reference

17 August 2017

Melinda Lynn

3

1 reference

17 August 2017

Ewa Mrozek

4

1 reference

17 August 2017

Bhuvaneswari Ramaswamy

5

1 reference

17 August 2017

Maryam B Lustberg

6

1 reference

17 August 2017

Robert Wesolowski

7

1 reference

17 August 2017

Susan Ottman

8

1 reference

17 August 2017

Sarah Carothers

9

1 reference

17 August 2017

Anissa Bingman

10

1 reference

17 August 2017

Raquel Reinbolt

11

1 reference

17 August 2017

Eric H Kraut

12

1 reference

17 August 2017

Charles L Shapiro

13

1 reference

17 August 2017

language of work or name

1 reference

21 February 2013

1 reference

Cancer Chemotherapy and Pharmacology

17 August 2017

1 reference

17 August 2017

71

1 reference

17 August 2017

5

1 reference

17 August 2017

1183-1190

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2112-2

17 August 2017

0 references

cites work

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Triple negative tumours: a critical review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Triple-negative breast cancer: therapeutic options

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Metaplastic breast carcinomas are basal-like tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Erlotinib in previously treated non-small-cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Prognostic markers in triple-negative breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710373

Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-013-2112-2

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23430121

12 December 2020

inferred from PubMed ID database lookup

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23430121

12 December 2020

inferred from PubMed ID database lookup

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23430121

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00280-013-2112-2

1 reference

release_6xsn3ap3pbe4dcohdyrzpw2iay

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6xsn3ap3pbe4dcohdyrzpw2iay

24 November 2022

mapped directly with Wikidata item

1 reference

17 August 2017

1 reference